Unknown

Dataset Information

0

C-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.


ABSTRACT: Background: The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). Methods: We evaluated whether HGF and c-Met were expressed in NK/T-cell lymphoma and the capacity of predicted c-Met HTL epitopes to induce antitumor responses in vitro. In addition, c-Met inhibitor was evaluated for the ability to inhibit TGF-? production in tumor and subsequently increase HTL recognition. Results: c-Met and HGF were expressed in NK/T-cell lymphoma cell lines, nasal NK/T-cell lymphoma specimens and patient serum samples. Moreover, HGF was shown to promote NK/T cell lymphoma (NKTCL) proliferation in an autocrine manner. Furthermore, we have identified three novel c-Met HTL epitopes that were restricted by several HLA-DR molecules. Notably, peptide-induced HTL lines directly recognized and killed c-Met expressing NK/T-cell lymphomas and various epithelial solid tumors. The c-Met specific HTLs could also recognize dendritic cells (DCs) pulsed with c-Met expressing tumor cell lysates. In addition, we observed that c-Met inhibition augmented HTL recognition by decreasing TGF-? production by tumor cells. Lastly, autophagy partly regulated the HTL responses against tumors. Conclusions: We identified novel c-Met HTL epitopes that can elicit effective antitumor responses against tumors expressing c-Met. Our results provide the rationale of combining c-Met targeting therapy and immunotherapy for NKTCLs and epithelial tumors.

SUBMITTER: Kumai T 

PROVIDER: S-EPMC4404796 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.

Kumai Takumi T   Matsuda Yoshinari Y   Ohkuri Takayuki T   Oikawa Kensuke K   Ishibashi Kei K   Aoki Naoko N   Kimura Shoji S   Harabuchi Yasuaki Y   Celis Esteban E   Kobayashi Hiroya H  

Oncoimmunology 20150201 2


<b>Background:</b> The expression of c-Met and its ligand HGF plays a critical role in cell proliferation and is involved in numerous malignancies. Because c-Met expression and its role in NK/T-cell lymphoma remain unclear, we studied the expression and function of c-Met in NK/T-cell lymphoma cells. In addition, we investigated the possibility that c-Met could function as a tumor-associated antigen for helper T lymphocytes (HTLs). <b>Methods:</b> We evaluated whether HGF and c-Met were expressed  ...[more]

Similar Datasets

| S-EPMC5937056 | biostudies-literature
| S-EPMC3429305 | biostudies-literature
| S-EPMC6832859 | biostudies-literature
| S-EPMC7724344 | biostudies-literature
| S-EPMC8223062 | biostudies-literature
| S-EPMC4561532 | biostudies-literature
| S-EPMC3980609 | biostudies-literature
| S-EPMC5266489 | biostudies-literature
| S-EPMC8533227 | biostudies-literature
| S-EPMC8044412 | biostudies-literature